Christopher Gerry - 14 Nov 2025 Form 3 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: President & PEO
Issuer ticker: SNSE
Reported as of: 14 Nov 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 24 Nov 2025, 19:01:47 UTC
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Gerry

Key filing fact

Christopher Gerry filed Form 3 for Sensei Biotherapeutics, Inc. (SNSE) on 24 Nov 2025.

Key facts

This page summarizes Christopher Gerry's Form 3 filing for Sensei Biotherapeutics, Inc. (SNSE).
0 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 24 Nov 2025, 19:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002097951 Primary reporting owner

Gerry Christopher

Relationship: President & PEO
Address: C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Signature: /s/ Christopher Gerry
Signature date: 24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNSE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,574
Date: 14 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNSE holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,750
Exercise price: $38.20
Footnotes: F2

SNSE holding Derivative

Sock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,100
Exercise price: $28.60
Footnotes: F3

SNSE holding Derivative

Sock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,881
Exercise price: $15.70
Footnotes: F4

SNSE holding Derivative

Sock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,999
Exercise price: $9.00
Footnotes: F5

SNSE holding Derivative

Sock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $9.52
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. 1,444 of the shares underlying the RSUs have fully vested and the remaining 130 shares vest in two equal installments on February 15, 2026 and February 15, 2027, in each case subject to the Reporting Person's continuous service with the Issuer through each such vesting date.

Footnote F2

The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, July 18, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F3

The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 15, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F4

The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 15, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F5

100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.

Footnote F6

The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 14, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .